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ABSTRACT

Jones, Melinda. M.S. Microbiology and Immunology M.S. Program, Wright State
University, 2012. Suppressor of Cytokine Signaling (SOCS) 1 & 3 Expression in HSV-1Infected and Interferon-γ-treated Neuro-2A Cells.

This study examined the effects of HSV-1 infection and IFN-γ treatment on
Neuro-2A cells. HSV-1 induces expression of SOCS1 and SOCS3 in infected cells,
inhibiting the ability of these cells to produce the pro inflammatory, antiviral cytokine
IFN-γ (Nowoslawski and Benveniste, 2011). SOCS1 and SOCS3 levels were determined
in IFN-γ-treated cells, virus-infected cells, and cells that were both IFN-γ-treated and
virus-infected. Results were compared with untreated, uninfected control cells. Flow
cytometry data analysis showed a slight decrease in SOCS1 and SOCS3 protein levels in
cells treated with IFN-γ for 6 hours compared to control cells. A significant decrease in
SOCS1 and SOCS 3 levels was found in cells treated with IFN-γ for 18 hours. Up
regulation of SOCS1 and SOCS3 expression was established in virus-infected Neuro-2A
cells but this increase was not statistically significant when compared to control cells.
However, culturing cells with IFN-γ for 6 hours prior to virus infection led to a
significant (50%) decrease in SOCS1 and SOCS3expression compared to cells treated
with IFN-γ alone. This showed that HSV-1 was not able to overcome the antiviral effects
of IFN-γ to up regulate SOCS1 and SOCS3 expression. Cytopathic effects assays were
performed to determine cell viability among cells treated with IFN-γ for 18 hours, cells
infected with virus for 48 hours, and cells treated with IFN-γ for 18 hours followed by 48

hour HSV-1 infection. Pre-treating cells with IFN-γ for 18 hours prior to infection with
HSV-1 (0.1 MOI) yielded a cell viability level similar to that of control cells
(untreated/uninfected). This indicates that IFN-γ is providing antiviral protection to most,
if not all of the cells. Applying these studies in a human cell line and eventually in an
animal model would be necessary to find the efficacy of IFN-γ as a HSV-1 therapeutic.
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Introduction

Herpes simplex virus type-1 (HSV-1) is a dsDNA virus that affects approximately
70-90% of the population (Cunningham et al., 2006). Although the primary infection is
efficiently controlled by the immune system in healthy individuals, the virus will persist
in a latent state for the life of the host. During latency, in which the virus resides in the
trigeminal ganglia, viral gene expression is minimal (Rautemaa et al., 2002). Reactivation
of the virus from neuronal latency is a common and potentially devastating occurrence,
responsible for a variety of pathological conditions including cold sores, herpes simplex
encephalitis (HSE), and herpes keratitis (Knickelbein et al., 2008; Sheridan et al. 2007)
The human body has intricate mechanisms for controlling viral invasions. One
such mechanism is the use of interferons. Interferon gamma (IFN-γ) is a type II
interferon that is rapidly produced after the recognition of pathogen-associated molecular
patterns (PAMPs) by an infected host cell (Bonjardim et al. 2009). It is produced mainly
by helper T cells and natural killer cells. The release of this cytokine activates cells of the
innate immune system that attempt to control the infection by killing infected cells and
inhibiting viral replication (Cunningham et al., 2006). This finely-tuned antiviral reaction
also signals a cessation response which is vital in preventing over-inflammation. This is
accomplished through the induction of suppressors of cytokine signaling (SOCS). SOCS
proteins negatively regulate inflammatory signaling pathways by facilitating the
ubiquination and proteosomal degradation of proteins associated with these pathways
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(Nowoslawski and Benveniste 2011). There are currently eight known members of the
SOCS family of proteins (SOCS1-7, CIS). All members contain a central SH2 domain
and a C-terminal SOCS box (Figure 1). SOCS1 and SOCS3 also contain a kinase
inhibitory region (KIR) which has been shown to interact directly with the JAK
autophosphorylation loop and inhibit IFN-γ signaling (Croker et al., 2008).
This is important to the study because it is known that herpes simplex virus type 1
is one of a number of viruses that is able to exploit host SOCS proteins for their benefit
(Nowoslawski and Benveniste 2011). Several cell lines have demonstrated an increase in
SOCS1 and SOCS3 levels upon infection with HSV-1 (Yokota et al., 2005; Frey et al.,
2009; Mahller et al., 2008). Increased SOCS1 and SOCS3 levels leads to reduced IFN-γ
signaling via inhibition of the JAK/STAT pathway (Figure 2). The process by which
HSV-1 increases SOCS expression has not been elucidated.
The interplay between these two proteins is important in balancing the beneficial
antiviral and harmful pro-inflammatory effects of IFN-γ signaling in the host cell. SOCS1
–deficient cells are resistant to viral infections (Fenner et al., 2006). However, SOCS1
and SOCS3-deficient mice are vulnerable to inflammatory diseases including
autoimmune disorders (Fenner et al., 2006; Qin et al., 2012).
As expected from this negative feedback mechanism, experiments with several
cell lines have shown down regulation in SOCS1 and SOCS3 expression when treated
with IFN-γ. These lines include keratinocytes, fibroblasts, and astrocytes (Frey et al.,
2009; Stark et al., 2004). However, cell lines in which SOCS genes are constitutively
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expressed often exhibit IFN-γ resistance (Fojtova et al., 2007; Vlotides et al., 2004).
Neurons are a cell type that constitutively expresses both SOCS1 and SOCS3. For this
reason, SOCS expression by neuronal cells treated with IFN-γ may differ from that of
other cell types.
The hypothesis of this study was that treatment of Neuro-2A cells with IFN-γ
prior to infection with HSV-1 would improve cell viability compared to cells infected
with virus alone. IFN-γ would cause down regulation of SOCS1 and SOCS3 expression
and provide protection from the virus. Basal SOCS1 and SOCS3 levels would be
established followed by levels determined after IFN-γ treatment, HSV-1 infection, and
after IFN-γ-treatment/HSV-1-infection. Cells would be treated with IFN-γ for 6 and 18
hours to determine the most effective length of treatment. The Neuro-2A cell line was
selected for this study due to the neuron being the site of viral latency and reactivation.
Figure 3 shows an immunofluorescent image of Neuro-2A cells stained with Phalloidin
which binds actin filaments and is commonly used in cellular imaging.

Literature Review

HSV-1
Herpes simplex virus type 1 is a dsDNA virus that undergoes cycles of latent and
lytic infection. It is estimated that HSV-1 affects approximately 70%-90% of adults
worldwide (Cunningham et al., 2006). Primary infection is usually controlled by the
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host’s immune system. Reactivation of the virus is common and exhibits as cutaneous or
mucocutaneous disease (Arduino and Porter, 2006). These occurrences are often mild and
are referred to as “cold sores.” Severe but less frequent manifestations include herpes
simplex encephalitis (HSE) and herpes stromal keratitis (HSK), with the latter being the
most common cause of corneal blindness (Sheridan et al., 2007).
HSV-1 usually infects the oral mucosa and replicates in stratified squamous
epithelium (Cunningham et al., 2006). Virus attached to host cell surface by way of
envelope glycoproteins gB, gC, gD, gH, and gL. Additional glycoproteins gE and gI
facilitate cell-cell spread (Rajcani and Vojvodova, 1998). After entering the stratified
squamous epithelium, virus moves via retrograde microtubule-associated transport to the
cell body of a neuron in the trigeminal ganglion where a life-long latent infection is
established. Sporadic reactivation of HSV-1 results in anterograde transport to the
original site of infection where viral replication and shedding occurs (Cunningham et al.,
2006; Diefenbach et al., 2008).
The in vivo environment during an HSV-1 infection involves a complex immune
response associated with many different cell types. Upon viral infection, activated NK
cells and T cells secrete large amounts of IFN-γ. This prevents neighboring cells from
becoming infected by inducing in them an antiviral state (Rottenberg and Kristensson,
2002). This is extremely important in the brain because neuronal cells lack the ability to
express MHC class I molecules for viral antigen presentation. Interferon is sufficient for
viral clearance in some diseases (Rodriguez et al., 2003). However, HSV-1 has evolved a
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mechanism to ward off the antiviral effects of IFN-γ by up regulating the levels of
SOCS1 and SOCS3. With high levels of these proteins, IFN-γ signaling is decreased,
diminishing its antiviral capacity.

SOCS1 and SOCS3
Suppressors of cytokine signaling (SOCS) proteins are inhibitors of cytokine
signaling pathways. The expression of SOCS proteins can be induced by cytokine
stimulation in a classical “negative feedback” loop (Croker et al., 2008). Eight members
comprise this family of proteins (CIS and SOCS1-SOCS7), each of which has a central
SH2 domain, an amino-terminal domain, and a carboxy-terminal domain known as the
SOCS box (Figure 1). SOCS1 and SOCS3 have an additional kinase inhibitory region
(KIR) that functions as a pseudosubstrate to inhibit kinase activity (Nowoslawski and
Benveniste, 2011). These two SOCS proteins are involved in IFN-γ regulation.

Interferon gamma
Interferon-γ is a powerful cytokine that influences the intracellular environment
by recognizing a distinct cell surface heterodimer receptor identified as interferon gamma
receptor 1/2 (IFNGR1/2) (Bonjardim et al., 2008). Once IFN-γ binds to its receptor,
Janus kinases (JAKs) are activated to initiate intracellular signaling (Remy et al., 1999).
JAK proteins phosphorylate tyrosine residues on the receptors, creating docking sites for
a pair of signal transducer and activator of transcription (STATs). These dimerize and
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translocate into the nucleus and bind to specific nucleotide sequences on the promoters of
target genes (O’Sullivan et al., 2006). This allows for transcription of antiviral genes such
as the enzyme protein kinase R (PKR) which is a serine-threonine kinase that binds to
and deactivates dsRNA structures (Rottenberg and Kristensson, 2002). IFN-γ also
stimulates bactericidal activity in phagocytes, stimulates antigen presentation through
class I and II major histocompatibility complex (MHC) molecules, induces chemokines,
orchestrates leukocyte-endothelium interactions, and affects cell proliferation and
apoptosis (Rodriguez et al., 2003). Cellular division is often inhibited in virus-infected
cells and in some situations, apoptosis is induced.

Materials and Methods

Cell Line
The CCL-131 murine Neuro-2A cell line (ATCC) is a neuroblastoma cell line derived
from the brain of a strain A albino mouse. Neuro-2A cells were cultured in 25 cm2 vented
cap cell culture flasks and incubated at 37°C in 5% CO2. Cells were maintained in
Dulbecco's Modified Eagle's Medium (DMEM) containing 10% heat inactivated fetal
bovine calf serum (FCS) and 1% penicillin/streptomycin. Cells were passaged twice a
week at a subcultivation ratio of 1:6. Culture flasks, DMEM, FCS, and Pen/Strep solution
were purchased from Fisher Scientific (Pittsburg, Pennsylvania).
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Cell Viability
Neuro-2A cells were subcultured at a ratio of 1:6 and incubated for 48 hours. At this
time, the flasks were approximately 40% confluent. They were then treated with IFN-γ
(100U/ml), infected with HSV-1 (0.1 MOI), or both. After an allotted time, cells were
removed from the cell culture flask using a dissociation reagent (Cell Stripper). Cells
were diluted with Trypan Blue and loaded onto a hemocytometer to obtain cell viability
counts. Cell Stripper and Trypan Blue were purchased from Fisher Scientific.

Immunofluorescent Staining
Neuro-2A cells were grown in slide chambers (Fisher Scientific) to approximately 40%
confluency. Cells were then treated with IFN-γ for 6 or 18 hours or with virus for 24
hours. Following treatment, medium was aspirated and cells were rinsed with 1% bovine
serum albumin (BSA) suspended in phosphate buffered saline (PBS). Cells were then
fixed using 4% Paraformaldehyde for 15 minutes and permeabilized using 0.1% TritonX/PBS for 10 minutes, both at room temperature. Blocking buffer, comprised of 5% Goat
Serum diluted in 1% BSA, was added for 1 hour at room temperature. After blocking,
SOCS1 and SOCS3 primary antibodies were added at 10µg/million cells and the slide
chambers were incubated overnight at 4˚C. Following incubation, cells were rinsed with
1% BSA. Secondary antibody (FITC) and Phalloidin were added at a 1:100 dilution for 1
hour. After a final rinse with 1% BSA, VectaShield mounting medium was applied and
slides were covered with a coverslip. Slides were then analyzed with fluorescence
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microscopy using the Spot Scope fluorescent microscope. SOCS1 and SOCS3 antibodies
were generously donated by Dr. Howard Johnson from the University of Florida
(Gainesville, Florida); FITC conjugated secondary antibody and Texas Red-Phalloidin X
was purchased from Life Technologies (Gaithersburg, Maryland); VectaShield mounting
medium supplied by Fisher Scientific.

Flow Cytometry
Cells were grown to approximately 40% confluency, at which time IFN-γ was added with
or without virus. After treatment, cells were removed using Cell Stripper and centrifuged
to obtain a cell pellet. The supernatant was removed and the cell pellet was resuspended
in 1 mL medium. A hemocytometer was used to obtain a cell count. Dilutions were made
to achieve the required one million cells for each flow sample.
Cells were centrifuged and rinsed twice with 1% BSA/PBS. Cells were then fixed with
4% Paraformaldehyde for 15 minutes at 4°C. After fixing, cells were rinsed three times.
Next, cells were permeabilized using 0.1% Triton-X/PBS for 15 at 4°C. Cells were then
rinsed three times. Blocking buffer (5% goat serum/3% BSA/PBS) was added to cells for
1 hour at room temperature. Following blocking, SOCS1 and SOCS3 primary antibodies
were added (10 µg) for 45 minutes at 4˚C. Cells were then rinsed three times. FITCconjugated secondary antibody, diluted in blocking buffer at a 1:100 dilution, was added
to cells for 45 minutes at 4˚C. Cells were then rinsed three times and suspended in ice
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cold PBS with 10% Fetal Calf Serum and 1% sodium azide. Samples were analyzed on
the Accuri C6 flow cytometer.

Interferon-γ Treatment
Cells were grown to approximately 40% confluence in cell culture flasks. IFN-γ was
added to flasks at a concentration of 100units/ml for 6 or 18 hours. IFN-γ was purchased
from Fisher Scientific.

Virus Infection
Cells were grown to approximately 40% confluence in culture flasks. Cells were then
removed using Cell Stripper and pelleted out. After centrifugation, the supernatant was
aspirated and the cell pellet was resuspended in 1 mL of medium. A hemocytometer was
used to obtain cell counts so multiplicity of infection (MOI) could be accurately
calculated. Cells were added to sterile media and cell culture flasks. HSV-1 was
administered to flasks at 0.1 MOI.

Results

Basal Levels of SOCS1 and SOCS3 are Similar in Neuro-2a Cells
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Immunofluorescent staining and flow cytometry was performed on Neuro-2A
cells to determine basal SOCS 1(Figure 4) and SOCS 3 (Figure 5) expression compared
to a Negative Isotype control. Images show comparable fluorescence (Figure 6) which is
supported by the flow data (Figure 7). Compared to the negative isotype control, SOCS1
expression levels ranged between 63.89% and 67.68%. SOCS3 levels ranged between
64.13% and 65.37%. The distribution of the proteins differed between the two types.
SOCS1 was found mostly in the nuclear region while SOCS3 appeared to be strictly
cytoplasmic.

Six Hour Interferon-γ Treatment Had No Significant Impact on SOCS Levels or
Cell Viability
Neuro-2A cells were treated with IFN-γ (100U/ml) for 6 hours to determine the
effect on SOCS expression. Immunofluorescent staining was performed and fluorescence
was not as intense as untreated cells (Figure 8). Flow cytometry showed a decrease in
expression with SOCS1 ranging between 55.42% and 64.19% and SOCS3 ranging
between 53.57% and 62.41% (Figure 9). This was a 9% decrease for both SOCS1 and
SOCS3. ANOVA analysis (Sigma Plot) showed this decrease to be of no statistical
significance compared to basal levels.

Eighteen Hour Interferon-γ Treatment Had a Significant Impact on SOCS Levels
but No Significant Impact on Cell Viability.
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Neuro-2A cells were treated with IFN-γ for 18 hours to determine the effect on
SOCS protein levels. Immunofluorescent staining was performed and fluorescent levels
were so low, the microscope could not record an image. Flow cytometry showed a
decrease in levels with SOCS1 ranging between 25.61% and 33.89% while SOCS3
ranged between 26.27% and 35.59% (Figure 10). This was a greater than 50% decrease
from basal levels for both SOCS1 and SOCS3. ANOVA analysis (Sigma Plot) showed
this to be a significant decrease. Cell viability experiments showed no loss of viability
with treatment (93% viable compared to 94% for control cells).

SOCS1 and SOCS3 Levels are Increased with HSV-1 Infection
Neuro-2A cells were infected with 0.1 MOI of virus. After 24 hours, SOCS1 and
SOCS 3 expression was assessed using immunofluorescent staining and flow cytometry.
Fluorescence was more intense in virus infected cells compared to control (Figures 11,
12). Flow analysis revealed SOCS1 expression levels ranging between 59.8% and
78.58% and SOCS3 levels ranging between 63.40% and 86.44% (Figure 13). While it
was shown that HSV-1 does increase SOCS1 and SOCS3 levels, ANOVA analysis
(Sigma Plot) found this not to be statistically significant from basal levels.

IFN-γ Treatment for 6 Hours Followed by 24 Hour Virus Infection Led to Further
Reduction in SOCS1 and SOCS3 Protein Levels
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Cells were treated with IFN-γ for 6 hours followed with virus infection at 0.1
MOI for 24 hours. Flow cytometry revealed a dramatic decrease in both SOCS1 and
SOCS3 expression. SOCS1 levels ranged between 15.51% and 20.84%. SOCS3 ranged
between 20.30% and 25.29% (Figure 14). This is a 73% decrease for SOCS1 and a 64%
decrease for SOCS3 from basal levels. Expression was lower than that of 18-hour IFN-γtreated cells by 17% and 13% for SOCS1 and SOCS3 respectively. Pre-treating cells
with IFN-γ for 6 hours prior to HSV-1 infection led to a decrease in SOCS1 and SOCS
expression by 79% and 84% respectively compared to HSV-1 infection alone.

IFN-γ for 18 Hours Prior to HSV-1 Infection Gives Protection From Virus
Cell viability experiments were conducted for Neuro-2A cells. Cells were treated
with IFN-γ for 18 hours, infected with HSV-1 for 48 hours, or treated with IFN-γ for 18
hours then infected with HSV-1 for 48 hours. Results were compared to control of
untreated/uninfected cells. Experiments were performed in quadruplicate. Control cells
exhibited a cell viability of 94%. Cells treated with IFN-γ for 18 hours showed viability
of 93%. Virus infected cell viability was 74%. Cells treated with IFN-γ for 18 hours prior
to virus infection had a cell viability of 91%. These data illustrate the ability of IFN-γ to
protect Neuro-2A cells from the cytotoxic effects of HSV-1 when added prior to
infection.
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Discussion

In this study it was shown through that Neuro-2A cells had similar basal levels of
SOCS1 and SOCS3. However, immunofluorescent images showed that the distribution of
the proteins differed. Antibodies to SOCS1 fluoresced more in the nucleus while
antibodies to SOCS3 seemed to fluoresce only in the cytoplasm. The nuclear localization
signal (NLS) located between the src-homology 2 domain and the SOCS box of SOCS1
but not other SOCS family members explain these results (Baetz et al, 2008).
Treating Neuro-2A cells with IFN-γ at a concentration of 100U/ml caused SOCS1
and SOCS3 protein levels to decrease. The 18 hour treatment showed a significant
decrease (p-value<0.05). There was expected to be an initial increase in SOCS protein
levels because it is a negative regulator of IFN-γ signaling however, this was not the case.
The concentration of IFN-γ used might have been too high or the time point tested may
have been too late. Another possibility is IFN-γ resistance. Neuronal and malignant cells
constitutively express SOCS genes and cells with constitutive SOCS expression may be
less sensitive to IFN-γ signaling (Fojtova et al., 2007).
Up regulation of SOCS1 and SOCS3 protein levels was achieved with HSV-1
infection, although ANOVA analysis (Sigma Plot) found the data to not be of statistical
significance. Due to the short half-life of SOCS proteins (1-2 hours) and the disputed
length of the HSV-1replication cycle, time lapse experiments would need to be
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performed to ascertain the time point following infection that SOCS levels were the
highest (Vuong et al., 2004).
Because IFN-γ treatment caused a decrease in SOCS expression, experiments
were performed to determine the effects on cells treated with IFN-γ for 6 hours prior to
HSV-1 infection. These cells had SOCS1 and SOCS3 protein levels that were decreased
by approximately 54% from cells that were IFN-γ-treated only. These data indicated that
the virus was not able to up regulate the SOCS levels enough to overcome the antiviral
effects of the interferon. A cytopathic effects assay was performed to establish if pretreatment with IFN-γ could indeed offer protection to virus-infected cells.
Treating Neuro-2A cells with IFN-γ for 18 hours prior to HSV-1 infection led to a
cell viability count similar to that of untreated/ uninfected control cells. This cytokine
prevents cells from becoming infected by inducing an antiviral state. This implies a wide
spectrum of changes that aim to inhibit the uptake, transcription, translation, and release
of infectious particles (Rottenberg and Kristensson, 2002). Future experiments need to
be performed on the IFN-γ-treated/virus-infected cells to find what percentage is actually
infected with the virus and if eventual clearance can be established. The biggest problem
with treating viral infections in neuronal cells is that neurons are post mitotic. Viral
clearance has to be accomplished in a way that does not destroy the cell. IFN-γ has the
ability to clear certain viral infections without killing the host cell.
Determining if latency is occurring in these cells by performing polymerase chain
reaction (PCR) would be important as well. It is not known at this point if IFN-γ is
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keeping the Neuro-2A cells from becoming infected by HSV-1 or if it is causing the virus
to immediately enter into a non-lytic, latent state.
It would also be important to better understand the localization patterns displayed
by SOCS1 and SOCS3 since only SOCS1 has a nuclear localization signal. It stands to
reason that herpes simplex virus exploits these two proteins somewhat differently. It is
quite possible that one plays a more important role in infection and latency than the other.
These in vitro studies would further need to be applied in a murine model. The in
vivo environment is vastly differently from an in vitro one with many other immune
factors at play. Establishing the efficacy or any toxicity of IFN-γ using animal models
would be necessary to proceed in using it as a possible prevention of HSV-1 pathogenesis
in humans.
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Figure 1: Schematic structure of suppressor of cytokine signaling (SOCS) proteins.
SOCS proteins are characterized by a central SH2 domain, a docking motif to
tyrosine-phosphorylated proteins, and a c-terminal SOCS box that recruits Elongin
B/C complex. SOCS1 and SOCS3 also possess a KIR domain, which plays an
important role in inhibition of JAK kinase activity. (Adapted from Fujimoto and
Naka, 2010).
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Figure 2: Activation of negative feedback loop by interferons via the
JAK/STAT pathway. (Adapted from Ivashkiv and Hu, 2004).

17

Figure 3: Immunofluorescent image of Neuro-2A cells stained with
Phalloidin. (Scale bar = 50µm)
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Figure 5: Immunofluorescent staining images of Phalloidin (top left), SOCS3
(bottom left), and Phalloidin/SOCS3 merged (right). (Scale bar = 50µm)
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Figure 6: Immunofluorescent staining images comparing basal SOCS1
(left) and SOCS3 (right) protein levels. (Scale bar = 50µm)
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Figure 7: Flow cytometry histograms showing basal SOCS1 (left) and
SOCS3 (right) expression compared to Negative Isotype control. The
expression of both proteins was similar.
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Figure 8: Immunofluorescent staining images showing SOCS1 (left)
and SOCS3 (right) protein levels after 6-hour IFN-y treatment
(100U/ml). (Scale bar = 50µm)
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Figure 9: Flow cytometry histograms showing SOCS1 (left) and
SOCS3 (right) expression after 6-hour IFN-y treatment
(100U/ml). Expression was not significantly decreased from
basal levels for either SOCS1 or SOCS3.
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Figure 10: Flow cytometry histograms showing SOCS1 (left) and SOCS3
(right) expression after 18-hour IFN-y treatment (100U/ml). Expression
was significantly decreased from basal levels for both SOCS1 and SOCS3.
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Figure 11: Immunofluorescent staining images of SOCS1 (left) and
SOCS3 (right) 24 hours post HSV-1 infection. (Scale bar = 50µm)
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Figure 12: Immunofluorescent staining images of SOCS1 (left) and SOCS3
(right) before (top) and after (bottom) infection with HSV-1 (0.1 MOI).
(Scale bar = 50µm)
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Figure 13: Flow cytometry histograms showing SOCS1 (left) and SOCS3
(right) expression 24 hours post HSV-1 infection (0.1 MOI). Expression was
slightly increased from basal levels for both SOCS1 and SOCS3.
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Figure 14: Flow cytometry histograms showing SOCS1 (left) and SOCS3 (right)
expression after 6-hour IFN-y treatment (100U/ml) and 24-hour HSV-1
infection (0.1 MOI). Expression was significantly decreased from IFN-γ-treated
only cells. (p-value<0.05)
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Figure 15: SOCS1 expression in Neuro-2A cells treated with IFN-y for 6 and 18 hours,
infected with virus for 24 hours, and cells treated with IFN-y for 6 hours then virus
infected for 24. Normalized to untreated/uninfected control cells. There was slightly
more than a half fold decrease in SOCS1 expression with 18-hour IFN-γ treatment and
an even greater decrease with IFN-γ treatment/virus infection. (*=p-value<0.05)
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Figure 16: SOCS3 expression in Neuro-2A cells treated with IFN-y for 6 and 18
hours, infected with virus for 24 hours, and cells treated with IFN-y for 6 hours
then virus infected for 24. Normalized to untreated/uninfected control cells.
There was approximately a 50% decrease in SOCS3 expression with 18-hour
IFN-γ treatment and an even greater decrease with IFN-γ treatment/virus
infection. (*=p-value<0.05)
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Figure 17: Cell viability table showing four separate trials and the average cell viability
count (last row) of those trials. IFN-γ treatment prior to infection yielded cell viability
similar to that of untreated/uninfected control Neuro-2A cells.
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